How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story
Ionis Pharmaceuticals and AstraZeneca recently reported that their Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin amyloidosis cardiomyopathy…